Skip to content Skip to footer
Subscribe Now
VERAXA Biotech & OmniAb
News

VERAXA Biotech Collaborates with OmniAb to Develop Novel Bispecific Antibody Drug Conjugate for Solid Tumors

Shots: VERAXA Biotech has entered into a co-discovery alliance with OmniAb to develop novel bispecific antibody drug conjugate (bsADC) targeting solid tumors using the former’s ADC linker tech & conjugation expertise & OmniAb’s suite of transgenic antibody discovery solutions As per the deal, VERAXA will initiate novel bsADC program targeting 2 cancer-related molecules, using OmniAb’s…
5 hours ago

Read more

BBOT
News

BridgeBio Oncology Therapeutics Reports the First Patient Dosing in P-I (KONQUER-101) Trial of BBO-11818 for Advanced Solid Tumors

Shots: BBOT has reported first pts dosing in its P-I (KONQUER-101) trial assessing BBO-11818 for advanced solid tumors, with trial enrolling pts globally In cellular assays, BBO-11818 showed pERK inhibition in selected KRAS G12D & G12V-mutant cell lines at lower concentrations, while reducing viability in KRAS G12D/G12V/G12C mutant cells & exhibiting >500-fold selectivity for KRAS…
April 3, 2025

Read more

Nanobiotix & Janssen
News

NANOBIOTIX and Janssen Amend Partnership to Develop and Commercialize JNJ-1900 (NBTXR3)

Shots: NANOBIOTIX & Janssen have amended their 2023 collaboration to develop & commercialize JNJ-1900 (NBTXR3), adjusting the deal value from $2.7B to $2.6B As per the revision, NANOBIOTIX will receive ~$1.77B in milestones related to cisplatin-ineligible HNSCC & inoperable stage 3 NSCLC, with ~$165M in milestones for China, South Korea, Singapore, & Thailand. J&J will cover…
March 18, 2025

Read more

News

Avenzo Therapeutics Join Forces with DualityBio to Develop AVZO-1418 (DB-1418) for Solid Tumors

Shots: Avenzo Therapeutics and DualityBio have signed an exclusive license agreement to develop, manufacture & commercialize the former’s AVZO-1418/DB-1418 across the globe (excl. Greater China) As per the terms, DualityBio will get $50M upfront, ~$1.15B development, regulatory and commercial milestones as well as tiered royalties in Avenzo’s territory AVZO-1418, an EGFR/HER3-targeting ADC developed…
January 8, 2025

Read more

News

Hanx Biopharmaceuticals Reports the First Patient Dosing with HX044 in P-I Clinical Evaluation

Shots: Hanx Biopharmaceuticals has dosed the first patient with HX044 under its P-I clinical evaluation for treating solid tumors The dose escalation & expansion P-I/IIa (HX044-I-01) trial will assess safety, tolerability, PK profile & initial efficacy of HX044 for the treatment of advanced solid tumor malignancies HX044 is a first-in-class bispecific antibody and…
January 3, 2025

Read more

Key Biosimilars Events of September 2024
INSIGHTS+

Key Biosimilars Events of September 2024

Shots:       Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency        Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients        The major highlights were the US FDA’s approval of Samsung Bioepis and…
October 3, 2024

Read more

Viewpoints_Efrat Kaduri
VIEWPOINTS

Off the Shelf Platform: Efrat Kaduri from Pluri Inc. In a Riveting Conversation with PharmaShots

Shots:  Recently, Pluri launched its placental allogenic MAIT cell platform for immunotherapy treatment of solid tumors. Mucosal Associated Invariant T (MAIT) cells offer better advantages as compared to conventional T cells  Today, we have with us Efrat Kaduri shedding light on the potential of placental MAIT cells in treating solid tumors  While highlighting the intellectual…
July 10, 2024

Read more

VIEWPOINTS_Robert Connelly_2023
VIEWPOINTS

Robert Connelly shares the highlights of the post-merger between Elicio Therapeutics & Angion Biomedica Corp.

Shots:  Robert Connelly, CEO of Elicio Therapeutics, shared his views on the aftermath of the merger between Elicio Therapeutics & Angion Biomedica Corp. The strategic merger is instrumental to further advance Elicio’s product candidates with a focus on advancing its proprietary lymph node targeting Amphiphile (AMP) technology to develop immunotherapies  Robert recapitulates data presented at ASCO…
October 9, 2023

Read more

Load more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]